MOTS-c
Mitochondrial Open Reading Frame of the 12S rRNA-c
16 Amino Acids · MW: 2,174.67 Da
Amino Acids
16
Molecular Weight
2,174.67 Da
Half-life
~hours (exact unknown)
Research Score
4.3
Studies
67
Storage
N/A
What is MOTS-c?
MOTS-c is a mitochondrial-derived peptide that regulates metabolic homeostasis and exercise physiology. It activates AMPK, improves insulin sensitivity, and mimics the metabolic effects of exercise. Discovered at USC, it represents a new class of mitochondrial signaling peptides.
Key Benefits & Mechanisms
Activates AMPK pathway (exercise mimetic)
Improves insulin sensitivity
Enhances fatty acid oxidation
Prevents diet-induced obesity
Improves exercise capacity
Anti-aging metabolic effects
Cellular stress resistance
Research Summary
MOTS-c is one of the most exciting recent peptide discoveries. Pre-clinical data strongly supports metabolic benefits. First human clinical trial completed at USC showing improved glucose metabolism. Represents a new paradigm of mitochondrial-derived peptide signaling.
Related Peptides
Semaglutide
GLP-1 Receptor Agonist
Semaglutide is a GLP-1 receptor agonist with proven efficacy for weight management and glycemic control. FDA-approved as Ozempic (diabetes) and Wegovy (weight management), it mimics the incretin hormone GLP-1 to regulate appetite and blood sugar.
MetabolicTirzepatide
GIP/GLP-1 Dual Receptor Agonist
Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist. FDA-approved as Mounjaro (diabetes) and Zepbound (weight management). It offers superior weight loss compared to GLP-1-only agonists by targeting two incretin pathways simultaneously.
MetabolicAOD-9604
Anti-Obesity Drug (Modified GH Fragment)
AOD-9604 is a modified fragment of human growth hormone (HGH fragment 177-191) specifically designed for fat metabolism. It stimulates lipolysis and inhibits lipogenesis without affecting blood sugar or tissue growth, making it a targeted fat-loss peptide without typical GH side effects.
MetabolicTesamorelin
Synthetic Growth Hormone Releasing Hormone
Tesamorelin is an FDA-approved synthetic analog of growth hormone-releasing hormone (GHRH). Approved as Egrifta for HIV-associated lipodystrophy, it reduces visceral adipose tissue while maintaining peripheral fat and improving body composition. Produces physiological GH release.
Metabolic